Alergia e Imunologia
Relato de caso | Trombose com trombocitopenia após vacina de RNA mensageiro–1273.
29 Jun, 2021 | 09:53hThrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine
Vacinas de mRNA contra SARS-CoV-2 induzem respostas persistentes do centro germinativo humano, sugerindo uma imunidade de longa duração.
29 Jun, 2021 | 09:52hSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature
Comentários: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical
Relacionado: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.
Comentário no Twitter (fio – clique para saber mais)
Just published @nature
A bonus factor after covid vaccination: germinal center factories for durable, antigen-specific, B cells and plasmoblasts induced by mRNA vaccination, as determined by lymph node aspirates from vaccinees https://t.co/5eR0gDSWHq@TheBcellArtist @WUSTLmed pic.twitter.com/C5xPSrh5Gw— Eric Topol (@EricTopol) June 28, 2021
[Preprint] Terceira dose da vacina da AstraZeneca propicia forte imunidade.
29 Jun, 2021 | 09:50hStudy: 3rd AstraZeneca shot gives strong immunity – Reuters
Estudo original (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet
Estudo randomizado | Desfechos similares com micofenolato mofetil vs. azatioprina em receptores de transplante renal recebendo baixas doses de ciclosporina sem corticoides.
29 Jun, 2021 | 09:43hEstudo randomizado de fase 2 | Imunogenicidade e reatogenicidade de dose de reforço da vacina da Pfizer-BioNTech em pacientes que receberam uma dose da vacina da AstraZeneca – “A vacina BNT162b2 (Pfizer), aplicada como segunda dose em indivíduos previamente vacinados com ChAdOx1-S (AstraZeneca), induziu uma resposta imune robusta, com perfil de reatogenicidade aceitável e controlável.”
28 Jun, 2021 | 10:48hComentários: Heterologous vaccine regimens against COVID-19 – The Lancet E
Comentário no Twitter (fio – clique para saber mais)
NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcas
et al. reports BNT162b2 given as a 2nd dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Read https://t.co/muL0XQxdjG. pic.twitter.com/BxPlXB8EF7— The Lancet (@TheLancet) June 26, 2021
Perspectiva | Uma dose de vacina é suficiente para quem já teve COVID? O que diz a ciência.
28 Jun, 2021 | 10:40hIs one vaccine dose enough if you’ve had COVID? What the science says – Nature
Relacionado: Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.
Comentário no Twitter
One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuW
Vaccination cards/proof should be modified here to equate prior covid as the 1st dose and not force people to get an unnecessary 2nd dose— Eric Topol (@EricTopol) June 27, 2021
“Long Covid”: estudo mostra que metade dos adultos jovens com COVID-19 apresentaram sintomas 6 meses depois da doença.
25 Jun, 2021 | 10:45hEstudo original: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine
Comentário no Twitter
Analysis of a prospectively enrolled cohort of patients with #SARSCoV2 infections reveals a high proportion who experienced #LongCovid symptoms at 6 months, despite being relatively young and having only mild to moderate acute #COVID19 symptoms https://t.co/fuW2QpfJog
— Nature Medicine (@NatureMedicine) June 23, 2021
[Preprint] “Long Covid”: 1/3 das pessoas infectadas apresentou sintomas de longa duração.
25 Jun, 2021 | 10:44hCovid-19: Third of people infected have long term symptoms – The BMJ
Estudo original (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London
Mais um estudo mostra que uma dose única de vacina de mRNA tem efeito máximo em pacientes com infecção prévia.
24 Jun, 2021 | 11:07hPrimary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano
Relacionado: France recommends single dose of vaccine if previous Covid infection detected. E [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. E Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Comentário no Twitter
Prior covid? Unless it's a severe case, one-dose mRNA vaccine adds considerable protection and nothing added by 2nd dose. This is now concordant w/ >20 studieshttps://t.co/8Qpuw193zk @acsnano pic.twitter.com/TJNbl8HPy9
— Eric Topol (@EricTopol) June 23, 2021
Relatório | Variantes do SARS-CoV-2 e vacinas.
24 Jun, 2021 | 11:06hSARS-CoV-2 Variants and Vaccines – New England Journal of Medicine